Tanya Sanderson, NP
Primary Care · Tupelo, MSNPI 1457907248
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,178 and has fallen 74.0% since, to $307 in 2025. Among primary care clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$381
- Biohaven Pharmaceutical Holding Company Ltd.$206
- SK Life Science, Inc.$183
- Genentech USA, Inc.$155
- Amneal Pharmaceuticals LLC$143
- Piramal Critical Care$135
- plus $2K from 42 others
What the payments were for
- Food & beverage$2,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,832 in reported general payments places this provider in the 90th percentile of 80 primary care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 63 | $913,508 |
| VyndamaxTafamidis | 40 | $898,586 |
| IbrancePalbociclib | 21 | $332,021 |
| TagrissoOsimertinib Mesylate | 15 | $235,027 |
| NubeqaDarolutamide | 16 | $208,156 |
| VenclextaVenetoclax | 21 | $194,222 |
| TymlosAbaloparatide | 67 | $169,050 |
| ForteoTeriparatide | 42 | $167,493 |
| OfevNintedanib Esylate | 13 | $158,905 |
| SprycelDasatinib | 14 | $155,473 |
| Fasenra PenBenralizumab | 21 | $117,130 |
| Humira PenAdalimumab | 12 | $74,266 |
| Dupixent SyringeDupilumab | 19 | $65,978 |
| OzempicSemaglutide | 20 | $36,882 |
| JardianceEmpagliflozin | 27 | $31,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Ibrance, Eliquis | $56 | $1,259,19383 claims |
| AstraZenecaTagrisso, Farxiga | $87 | $252,57730 claims |
| AbbVieVenclexta | $65 | $194,22221 claims |
| Boehringer IngelheimOfev, Jardiance | $15 | $190,77540 claims |
| Lilly USA, LLCForteo | $60 | $167,49342 claims |
| Novo NordiskOzempic | $34 | $36,88220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 80 primary care providers in Mississippi.
Other primary care in Tupelo
- Sarah HarringtonTupelo$11K
- Mary EatonTupelo$4K
- Wanderful PorterTupelo$380
- Alisha McArthur WilkesRidgeland$17K
- Katrina BlackardSouthaven$14K
- Julie HarperNewhebron$10K
- Hannah IvisonJackson$10K
- Irene WilsonSouthaven$4K
- Amanda EllisKosciusko$3K
- Charity MilamSouthaven$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.